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Abstract Sideromycins are antibiotics covalently
linked to siderophores. They are actively transported
into gram-positive and gram-negative bacteria.
Energy-coupled transport across the outer membrane
and the cytoplasmic membrane strongly increases
their antibiotic efﬁciency; their minimal inhibitory
concentration is at least 100-fold lower than that of
antibiotics that enter cells by diffusion. This is
particularlyrelevantforgram-negativebacteriabecause
the outer membrane, which usually forms a permeabil-
itybarrier,inthiscaseactivelycontributestotheuptake
of sideromycins. Sideromycin-resistant mutants can be
used to identify siderophore transport systems since the
mutations are usually in transport genes. Two sider-
omycins, albomycin and salmycin, are discussed here.
Albomycin, a derivative of ferrichrome with a bound
thioribosyl-pyrimidine moiety, inhibts seryl-t-RNA
synthetase. Salmycin, a ferrioxamine derivative with a
bound aminodisaccharide, presumably inhibts protein
synthesis.Crystalstructuresofalbomycinboundtothe
outer membrane transporter FhuA and the periplasmic
binding protein FhuD have been determined. Albo-
mycinandsalmycinhavebeenusedtocharacterizethe
transport systems of Escherichia coli and Streptococ-
cus pneumoniae and of Staphylococcus aureus,
respectively. The in vivo efﬁcacy of albomycin and
salmycin has been examined in a mouse model using
Yersinia enterocolitica, S. pneumoniae, and S. aureus
infections. Albomycin is effective in clearing infec-
tions, whereas salmycin is too unstable to lead to a
largereductioninbacterialnumbers.Therecoveryrate
ofalbomycin-resistantmutantsislowerthanthatofthe
wild-type, which suggests a reduced ﬁtness of the
mutants. Albomycin could be a useful antibiotic
provided sufﬁcient quantities can be isolated from
streptomycetes or synthesized chemically.
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Introduction
Iron,anessentialelement,iscontainedinactivecenters
of many redox enzymes. Under oxic conditions, it
occurs in nature as an insoluble Fe
3? hydroxide
polymer and in eukaryotic hosts tightly bound to
transferrin and lactoferrin. However, bacterial and
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3? speciﬁcity
andafﬁnity,makeFe
3?available.Themicroorganisms
synthesizeandsecretethesiderophores,whicharethen
taken up as Fe
3?-complexes via speciﬁc active trans-
port systems. Gram-negative bacteria concentrate
Fe
3?-siderophores at the cell surface by binding them
to very speciﬁc high-afﬁnity transport proteins. The
Fe
3?-siderophoresarethentransportedacrosstheouter
membraneintotheperiplasmandfromthereacrossthe
cytoplasmic membrane into the cytoplasm, where iron
isreleasedfromthesiderophoresandincorporatedinto
heme and non-heme iron proteins.
The term sideromycin was coined for naturally
occurring Fe
3?-siderophores that are covalently
linked to an antibiotic moiety. Sideromycins were
actually discovered prior to siderophores in a sceen-
ing for new antibiotics and were originally called
sideramines or siderochromes (Nu ¨esch and Knu ¨sel
1967). Siderophores were later found to antagonize
the activity of sideromycins, and it was initially
assumed that the siderophores competed with the
sideromycins at the sideromycin target sites. It was
then shown that siderophores and sideromycins
compete for common uptake systems.
Sideromycins are taken up by Fe
31-siderophore
transport systems
Crystal structures of the proteins responsible for the
transport of Fe
3?-siderophores across the outer
membrane have been determined. The various pro-
teins are similar in structure and consist of 22 b
strands that form b barrels with an internal pore
completely closed by a globular domain, called the
plug (summarized by Wiener 2005; Krewulak and
Vogel 2008; Schalk 2008). Up to ten amino acid
residues at the surface of the transporters bind the
Fe
3?-siderophores very tightly with KD values in the
range of 1 nM.
Structural transitions must occur to release the
Fe
3?-siderophores and to move the plugs to open the
pores. Both processes require energy, which is not
available in the outer membrane. Energy is provided
by the proton-motive force of the cytoplasmic
membrane and is transduced from there to the outer
membrane by the Ton protein complex, consisting of
TonB, ExbB, and ExbD. These three proteins are
embedded in the cytoplasmic membrane (Fig. 1). The
stoichiometry of the TonB:ExbB:ExbD proteins in
cells, but not necessarily in the complex, is 1:7:2.
TonB interacts with the outer membrane transport
proteins, as has been revealed by genetic, biochem-
ical, and protein crystallographic methods. The C-
proximal end of TonB forms a three-stranded b-sheet,
to which the b-strand of the N-terminal end of the
transporters binds (Fig. 1). Prior to the crystallo-
graphic proof of binding, the N-terminal end was
presumed to bind to TonB based on various pieces of
evidence: sequence similarities among transporters,
mutations that inactivate the transporters, and sup-
pressor mutations in the C-proximal end of TonB that
restore the activity of the TonB box mutants. This
region was therefore designated the TonB box
(Schramm et al. 1987). The Ton complex responds
to the proton-motive force by altering the conﬁrma-
tion of TonB to its energized form (Larsen et al.
1999). It is assumed that interaction of the energized
form with the outer membrane transporters then alters
the conformation of the transporters, resulting in the
release of the bound Fe
3?-siderophores, the opening
of a pore in the transporters, and the diffusion of the
Fe
3?-siderophores into the periplasm.
Only a few naturally occurring sideromycins have
been found, among them albomycin and salmycin
(Fig. 2). A wide spectrum of siderophore–antibiotic
conjugates have been chemically synthesized.
Although the antibiotic moieties account for a
substantial part of the sideromycins and drastically
change the shape of the siderophore from which they
are derived, the sideromycins are nevertheless rec-
ognized and transported by the Fe
3?-siderophore
transport proteins. The transport proteins identify the
Fe
3?-complexes and tolerate additions to an astound-
ing degree. It seems that whatever is bound to the
active site of the transport proteins is also transported.
The most extreme case is the transport of a rifamycin
derivative, designated CGP 4832, by the FhuA outer
membrane transporter—CGP 4832 in the crystal
structure with FhuA shows no structural similarity
with ferrichrome, the substrate of FhuA (Ferguson
et al. 2001). Of the ten amino acid residues of FhuA
that bind ferricrocin, a derivative of ferrichrome, nine
also bind CGP 4832. The rifamycin derivative,
however, is not transported across the cytoplasmic
membrane, probably because it is not recognized by
the FhuBD proteins that transport ferrichrome into
the cytoplasm (Fig. 1).
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Among the sideromycins, albomycin has been studied
in most detail. Albomycin consists of a siderophore
structurally similar to ferrichrome with a bound
thioribosyl pyrimidine antibiotic (Fig. 2). Inside
E. coli cells, the antibiotic is cleaved off the Fe
3?
carrier by peptidase N, encoded by pepN. The anti-
bioticstaysinsidethecells,whereastheiron-freecarrier
is excreted. pepN mutants are albomycin resistant;
therefore, release of the antibiotic from the carrier is
required for activity. Without cleavage, albomycin
functions only as a siderophore and carries iron into
cells (Hartmann et al. 1979; Braun et al. 1983).
Albomycin is taken up via the ferrichrome trans-
port system across the outer membrane and the
cytoplasmic membrane of E. coli and other gram-
negative bacteria. It binds to FhuA well above the
surface of cells. It assumes two different conforma-
tions in the FhuA–albomycin crystal structure: an
extended form and a compact form (Ferguson et al.
2000). The extended form has the same ten amino acid
binding sites as ferrichrome. Four additional residues
bind the antibiotic.
After the FhuA- and Ton-dependent uptake across
the outer membrane, albomycin binds to FhuD in the
periplasm (Fig. 1). Albomycin and ferrichrome bound
to FhuD have dissociation constants of 5.4 and 1 lM,
respectively (Rohrbach et al. 1995). FhuD then
delivers albomycin to FhuB. FhuD binds to FhuB in
this process, as indicated by chemical cross-linking of
substrate-loaded as well as unloaded FhuD to FhuB
and the prevention of FhuB proteolysis when FhuB is
incubated with FhuD (Rohrbach et al. 1995). The two
independently folded domains of FhuD are connected
by an a-helix that confers rigidity to the molecule. The
large movement of the two domains upon substrate
binding and release observed in most other periplas-
mic binding proteins (Venus ﬂytrap-like fashion) does
not occur in FhuD. A molecular dynamics simulation
has revealed a closure of 6 of a C-terminal domain
upon release of the siderophore; this movement seems
to be sufﬁcient for the distinction of unloaded and
loaded FhuD by FhuB (Krewulak et al. 2005).
Fig. 1 Albomycin and ferrichrome transport system of E. coli.
Both compounds are transported by the same proteins: FhuA in
the outer membrane, FhuD in the periplasm, and FhuB in
the cytoplasmic membrane. FhuC is the ATPase that provides
the energy for transport across the cytoplasmic membrane. The
proteins TonB, ExbB, and ExbD form a complex that provides
energy for transport across the outer membrane. The trans-
membrane topology of the cytoplasmic membrane proteins but
not the stoichiometry of TonB, ExbB, and ExbD is shown. The
complete crystal structures of FhuA (red) and FhuD (green)
loaded with albomycin and the crystal structures of periplasmic
portions of TonB and ExbD are shown. The 22 anti-parallel
b-strands of FhuA form a b-barrel (blue-green) that is closed
by a globular domain (yellow). The TonB box of FhuA forms
with TonB a four-stranded b-sheet. The structure of the linkage
between the membrane segment and the crystallized domain of
TonB is unknown
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123In contrast to most dimeric ABC transport proteins
in the cytoplasmic membrane, FhuB consists of a
single polypeptide with 12 transmembrane segments
(Groeger and Ko ¨ster 1998). The N- and C-terminal
halves are homologous. FhuB point mutations in
regions conserved among ABC transporters confer
albomycin resistance and lack of ferrichrome trans-
port (Ko ¨ster and Bo ¨hm 1992). It is not known whether
there is speciﬁc albomycin binding to FhuB in the
cytoplasmic membrane. In this and other ABC import
systems, substrate speciﬁcity is primarily determined
by binding of the substrate to the periplasmic binding
protein (Davidson et al. 2008). Binding of substrate-
loaded FhuD to FhuB presumably opens a channel in
FhuB and triggers ATP hydrolysis by FhuC.
FhuCisatypicalNBDprotein(ATPase),asfoundin
other ABC transporters. Mutations in predicted ATP
binding sites inactivate FhuC, abolish ferrichrome
transport, and confer albomycin resistance (Schultz-
Hauser et al. 1992).
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Fig. 2 Chemical structures
of ferrichrome, albomycin,
ferrioxamine B, and
salmycin. The co-crystals of
ferrichrome and albomycin
with FhuA reveal their
structures in the protein-
bound form (Fig. 1)
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transporters (Hollenstein et al. 2007) and biochemical
studies of ABC transporters reconstituted in lipo-
somes (Davidson et al. 2008) reveal the following
common features, which might also apply to ferri-
chrome and albomycin transport via FhuBCD. The
channel in the cytoplasmic membrane is formed by
12 a-helices. They assume an outward-facing or
inward-facing conformation. Unidirectional transport
is achieved by the ATP-driven conversion of the
inward-facing state to the outward-facing state.
Binding of two ATP molecules at the interface
between the two nucleotide-binding domains (ATP-
ases) closes the gap between the two ATP-binding
sites and also causes closure of the helices that bind
to the two NBD molecules. The helices ﬂip from the
inward-facing to the outward-facing conformation.
This structural transition might be transmitted to the
substrate-loaded binding protein, which opens and
releases the substrate to the inner membrane trans-
porter. ATP hydrolysis and dissociation of ADP ? Pi
from the ABC transporter reset the inward-facing
conformation, allowing the substrate to enter the
cytoplasm.
Transport of albomycin and salmycin into
Streptococcus pneumoniae and Staphylococcus
aureus
Since salmycin inhibits almost exclusively gram-
positive bacteria (see below), uptake of salmycin has
been studied in the gram-positive S. pneumoniae and
S. aureus. Mutants of both organisms display cross-
resistancetosalmycinandalbomycin,andferrichrome
and ferrioxamine B inhibit the toxicity of both
antibiotics. These results indicate that salmycin and
albomycin are taken up by the same transport system.
The target site of albomycin is known, but that of
salmycin is not. Salmycin consists of a ferrioxamine
B derivative (danoxamine) and an aminodisaccharide
(Ve ´rtesy et al. 1995). It inhibits an unidentiﬁed step
of protein synthesis. Target-site mutants common to
albomycin and salmycin cannot be isolated because
the completely different antibiotics exclude the same
toxicity mechanism. Since albomycin is more readily
available, mostly it has been used to isolate transport
mutants of Streptococcus peumoniae and to charac-
terize the mutated genes and their products. A few
S. aureus mutants have been selected with salmycin
(Gwinner and Braun, unpublished results).
Several iron transport systems have been predicted
in S. pneumoniae based on comparison of its genome
sequence with other genome sequences (Brown et al.
2002). These systems have been shown experimen-
tally to be related to iron transport, but siderophores
have not been identiﬁed. The identiﬁcation of sidero-
phores in S. pneumoniae is difﬁcult because the
bacterium only grows on complex media, such as
blood agar. The use of sideromycins circumvents this
problem since resistant mutants can be isolated on
complex media and these mutants usually have
modiﬁed transport proteins (Pramanik and Braun
2006). Using this approach, the albomycin transport
genes were identiﬁed (Fig. 3). Additional mutants
were isolated by transposon mutagenesis and insertion
duplication mutagenesis. Chromosomal fhuB, fhuD,
and fhuG mutants were isolated. The transport defects
were veriﬁed by comparing growth promotion of the
wild-type and the mutants by the Fe
3?-hydroxamates
and by comparing the transport rates of radiolabeled
[
55Fe
3?]ferrichrome and radiolabeled [
55Fe
3?]ferriox-
amine B of the wild-type with that of mutants. In
addition, the Fe
3?-hydroxamates cross-streaked on
nutrient agar with the antibiotics interfered with
growth inhibition of the antibiotics. The FhuD binding
fhuD fhuB fhuG fhuC
-23 nt             -1 nt              -1 nt
fhuB fhuC fhuD1 fhuG fhuD2
35 nt             -4 nt              ~1.4 mnt     ~0.25 mnt      
Streptococcus pneumoniae R6
Staphylococcus aureus Mu 50
Fig. 3 Arrangement of the fhu genes on the genome of S. pneumoniae and S. aureus. The number of nucleotides (nt, nucleotides;
mnt, million nucleotides) between the genes is indicated; a negative number indicates that the genes overlap
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123protein has been isolated and shown to bind ferri-
chrome, ferrioxamine B, albomycin, and salmycin
(Pramanik and Braun 2006). This study shows that
the S. pneumoniae genome encodes a single Fe
3?-
hydroxamate transport system, through which ferri-
chrome, ferrioxamine B, and the structurally related
antibiotics albomycin and salmycin are taken up into
the cells.
The transport system of S. aureus for Fe
3?-
hydroxamates has been characterized without the
use of sideromycins (Sebulsky et al. 2003; Speziali
et al. 2006). S. aureus grows on simple deﬁned
media, which allow addition of Fe
3?-siderophores as
the sole iron source. The transport system exhibits
broad substrate speciﬁcity and takes up ferrichrome
and the Fe
3?-complexes of aerobactin, coprogen,
Desferal
, and rhodotorulic acid. Five involved genes
have been identiﬁed, four of which are required to
promote growth by ferrichrome on iron-limited
medium. The genome of S. aureus contains two
fhuD genes, which are located distant from the
fhuBCG genes (Fig. 3). Both fhuD genes encode
substrate-binding proteins that are anchored by an N-
terminal lipid to the cytoplasmic membrane. Mutant
H430 fhuD1 is sensitive to salmycin and albomycin
and transports ferrioxamine and ferrichrome at rates
similar to the wild-type. Mutant H364 fhuD2 trans-
ports ferrioxamine B with only 10% of the wild-type
rate and is nearly salmycin resistant; in contrast, the
ferrichrome transport rate is 20% of the wild-type
rate, which is sufﬁcient to confer full albomycin
sensitivity (Gwinner and Braun, unpublished results).
Mutant H431 fhuD1 fhuD2 does not transport either
siderophore and is resistant to both antibiotics. The
fhuD2 mutant has a lower growth response to
ferrichrome and ferrioxamine B than the fhuD1
mutant and a narrower speciﬁcity, i.e., aerobactin
and coprogen do not support growth, in contrast to
the fhuD1 mutant, which grows on all four Fe
3?-
hydroxamates (Sebulsky and Heinrichs 2001). FhuD2
is the preferred binding protein for the antibiotics and
the Fe
3?-hydroxamates. A spontaneous salmycin-
resistant fhuD2 mutant with a mutation that truncates
the protein from 302 to 279 residues still confers
albomycin sensitivity. Either the C-proximal end is
important for salmycin binding or the expression level
of the protein is insufﬁcient for salmycin uptake but
sufﬁcient for albomycin uptake. Additional spontane-
ous salmycin-resistant mutants with deletions in the
fhuB gene or insertions in the fhuG gene that encode
thetransportproteinsinthecytoplasmicmembraneare
cross-resistant to albomycin (Gwinner and Braun,
unpublished results). These studies demonstrate a
singleFe
3?-hydroxamatetransportsysteminS.aureus
through which ferrichrome, ferrioxamine B, and the
structurally related antibiotics albomycin and salmy-
cin are taken up into cells.
Active transport strongly reduces the minimal
inhibitory concentration
For many antibiotics, the diffusion rate across the cell
membranes into the cytoplasm is poor. This is
frequently a serious problem in antibiotic therapy
against especially gram-negative bacteria since the
outer membrane reduces permeation to such an extent
that the minimal inhibitory concentration required
reaches toxic levels. In contrast, for sideromycins, the
outer membranes and the cytoplasmic membranes do
not serve as permeability barriers, but rather actively
contribute to the entry of the antibiotics to their targets
in the cytoplasm. Active transport reduces the min-
imal inhibitory concentrations more than a 100-fold
(Braun 1999). This is illustrated by the following
examples.
In a screening for new antibiotics in Streptomyces
species, the seryl thioribosyl pyrimidine moiety of
albomycin free of the siderophore (designated SB-
217452) was isolated and shown to inhibit in vitro the
seryl-tRNA synthetases of S. aureus and rats (Stef-
anska et al. 2000). SB-217452 structurally resembles
seryl adenylate, which explains the inhibition of seryl-
tRNA synthetases. The high in vitro activity against
isolated seryl-t-RNA synthetase (Table 1) conﬂicts
with the poor in vivo activity against gram-positive
and gram-negative bacteria. Without a siderophore
carrier, the antibiotic moiety is 30,0000-fold less
effective against S. aureus and E. coli because it
barely enters these cells. Other bacteria are somewhat
more sensitive to SB-217452, but still 1,000-fold less
sensitive than to albomycin.
Another example is the semi-synthetic rifamycin
derivative CGP 4832, which is[200-fold more active
against E. coli and Salmonella than rifamycin. The
enhanced activity of CGP 4832 rests on transport by
the FhuA transporter across the outer membrane into
the periplasm (Pugsley et al. 1987). Energy-coupled
8 Biometals (2009) 22:3–13
123transport results in an accumulation in the periplasm,
which accelerates diffusion across the cytoplasmic
membrane, giving rise to an increased cytoplasmic
concentration. The higher efﬁcacy of CGP 4832 is
not caused by a stronger inhibition of the DNA-
dependent RNA polymerase than rifamycin. Ferri-
mycin A1 and danomycin are other sideromycins
derived from ferrioxamine B that are taken up by the
ferrioxamine B transport system. Ferrimycin A1
speciﬁcally inhibits protein synthesis, as has been
shown by incorporation of radiolabeled phenylala-
nine into whole cells of S. aureus (Nu ¨esch and
Knu ¨sel 1967; Urban et al. 2007).
Besides sideromycins of the Fe
3?-hydroxamate
type, natural sideromyins of the Fe
3?-catecholate
type occur. Microcins, for example, are antibacterial
peptides, some of which are modiﬁed covalently by
Fe
3?-catecholates (Braun et al. 2002; Miethke and
Marahiel 2007). In microcin MccE492m (m = mod-
iﬁed), a linear trimer of N-(2,3-dihydroxybenzoyl)-
L-serine (DHBS) is bound to the C-terminal serine 84
via a b-D-glucose linker (Thomas et al. 2004). DHBS
is the precursor of the cyclic trimer enterobactin,
which is a potent siderophore of E. coli and related
bacteria. The DHBS monomer, dimer, and trimer also
bind iron and serve as Fe
3?-siderophores. They are
taken up into E. coli via the FepA, Fiu, and Cir outer
membrane transporters. These transporters are also
required to confer high sensitivity to MccE492m. The
minimal inhibitory concentration of MccE492m
required to kill E. coli B is 0.04 lM, whereas
0.3 lM is required for the unmodiﬁed MccE492.
The fepA ﬁu double mutant exhibits an eight-fold and
the fepA ﬁu cir triple mutant a 200-fold reduction in
sensitivity to MccE492m. tonB mutants show a
strong reduction in sensitivity, whereas, unexpect-
edly, an exbBD deletion mutant is unaffected. This is
a surprising result because TonB requires ExbBD to
function. Since ExbBD can be partially replaced
by TolQR (Braun and Herrmann 1993), it would
be worthwile to study the TolQR dependence of
MccE492m uptake.
A number of catechol-derived antibiotic conjugates
that confer 100–10,000-fold higher antibiotic activity
than the antibiotic without iron carrier have been
chemically synthesized (compiled in Braun 1999).
Cephalosporins linked to Fe
3?-catecholates are taken
up by the Fe
3?-catechol transporters across the outer
membranesofE.coliandPseudomonasaeruginosa,and
their activity exceeds that of the unsubstituted cephalo-
sporins by several orders of magnitude. Since
cephalosporins inhibit cross-linking of murein (peptido-
glycan) in the periplasm, they must be transported only
across the outer membrane. Susceptibility of E. coli to
Fe
3?-catechol cephalosporins is decreased more than
1,000-fold by a mutation in tonB, w h i c hi sr e q u i r e df o r
activetransport,and100–1,000-foldinmutantsthatlack
two or three of the catecholate outer membrane trans-
porters FepA,Fiu,andCir(Watanabeetal.1987; Curtis
et al. 1988; Silley et al. 1990). For high efﬁcacy of the
conjugates, iron must be present to form the Fe
3?-
complexes,buttheironconcentrationmustbelowtode-
repress transcription of the transport genes in the strains
tested. Such conditions occur at sites of infections in
mammals.
When the Fe
3?-siderophore conjugates are trans-
ported by a single outer membrane protein, resistant
bacteria frequently develop. Such mutants show a
reduced growth rate if the particular Fe
3?-sidero-
phore transport system is needed at the site of
infection or at the location in the environment.
Slower growth of pathogenic bacteria would increase
the chance of the native and the acquired immune
systems to cope with the infection. This also holds
true for tonB mutants because many bacteria encode
only one tonB gene, and this gene is essential for the
Table 1 Sensitivity to
albomycin and SB-217452
(albomycin without
Fe
3?-siderophore carrier)
a Whole cells. Data from
Stefanska et al. (2000) and
Gwinner and Braun
(unpublished)
Substrate Sensitivity to
Albomycin SB-217452
Seryl-tRNA synthetase
(Staphylococcus aureus, mouse)
Inactive 8 ng/ml
Staphylococcus aureus
a 8 ng/ml 256 lg/ml
Escherichia coli
a 8 ng/ml 256 lg/ml
Streptococcus pyogenes
a 8 ng/ml 16 lg/ml
Moraxella catarrhalis
a 8 ng/ml 8 lg/ml
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3?-siderophores and heme. When
more than one tonB gene is encoded, the TonB
proteins display speciﬁcity for certain iron transport
systems (Cescau et al. 2007; Wyckoff et al. 2007).
To overcome the resistance problem, a cephalo-
sporin was chemically conjugated to hydroxamates
and catecholates that use different transporters
(Ghosh et al. 1996). The mixed-ligand siderophore–
b-lactam conjugates are less active than the cepha-
losporin, except for one compound, which inhibits
Acinetobacteratamuchlowerconcentration(0.03 lg/
ml) than cephalosporin (64 lg/ml). Despite the
mixed ligand and the lower frequency of double
mutants than single mutants, resistant E. coli and
P. aeruginosa cells developed on agar plates. Such
multiple mutants may be subject to iron starvation,
which limits proliferation and pathogenicity in the
hosts.
Activity spectrum of albomycin and salmycin
Deﬁned bacterial laboratory strains and clinical
isolates have been used to determine growth inhibi-
tion by albomycin and salmycin. Albomycin is highly
activeagainstgram-negativeEnterobacteriaceaeexcept
Proteus and related Morganella strains (Table 1).
Proteus and Morganella are transport deﬁcient
(Pramanik et al. 2007) because they lack the fhu
transport genes, as has been shown for several
Proteus mirabilis strains (Pramanik et al. 2007;
Pearson et al. 2008). This result is unexpected since
the genomes of all other tested Enterobacteriaceae
encode the fhu transport system. Albomycin kills
only a few gram-positive bacteria, among them
pathogens of great clinical importance, such as
S. aureus and S. pneumoniae. Salmycin displays the
same activity spectrum with gram-positive bacteria as
albomycin, except that salmycin but not albomycin is
active against Streptococcus agalactiae. In contrast to
albomycin, salmycin is inactive against most gram-
negative bacteria (Table 2). Exceptions are Hafnia
alvei, Citrobacter freundii, and some strains of
Yersinia enterocolitica, which are sensitive to
10 ng/ml salmycin, the concentration that inhibits
gram-positive bacteria. Resistance of the gram-neg-
ative bacteria to salmycin is most likely caused by the
speciﬁcity of the outer membrane transporters, which
exclude salmycin. After transformation of an E. coli
K-12 strain with the foxA gene of Y. enterocolitica,
E. coli becomes sensitive to salmycin. The foxA gene
encodes the outer membrane transport protein that
takes up ferrioxamine B, the iron carrier of salmycin.
This also shows that the E. coli FhuBCD proteins
transport salmycin.
In general, outer membrane transporters are more
speciﬁc than cytoplasmic membrane transporters. For
example, E. coli transports ferrichrome, aerobactin,
and ferrioxamine B by a common transport system
across the cytoplasmic membrane but uses speciﬁc
transporters across the outer membrane for each of
the Fe
3?-hydroxamates.
Table 2 Activity spectrum of albomycin and salmycin
Pathogenic strains (numbers
tested)
Albomycin
sensitivity
Salmycin
sensitivity
Escherichia coli ?-
Serratia marcescens (3) ?-
Serratia liquefaciens (3) ?-
Klebsiella pneumoniae (4) ?;
Shigella dysenteriae (2) ?-
Shigella ﬂexneri (2) ?-
Shigella sonnei (1) ?-
Salmonella heidelberg H1 (1) ?-
Salmonella enteritidis (2) ?-
Yersinia enterocolitica (5) ?;
Proteus mirabilis (19) --
Proteus vulgaris (7) --
Morganella morganii (6) --
Hafnia alvei ND ?
Citrobacter freundii ND ?
Pseudomonas aeruginosa (12) --
Enterococcus faecium (3) --
Enterococcus faecalis (3) --
Enterobacter cloacae ND ?
Streptococcus pneumoniae (5) ??
Streptococcus agalactiae (2) -?
Streptococcus pyogenes (3) --
Staphylococcus epidermidis (3) --
Staphylococcus aureus (5) ??
Listeria monocytogenes (2) --
Bacillus subtilis (2) ??
Staphylococcus carnosus (1) ??
ND, not determined; ?, sensitive; -, insensitive; ;, some
strains are sensitive, other strains are not
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mouse infection models
To test the protection by albomycin of mice against
infection by pathogenic bacteria, the gram-positive
S. pneumoniae strain D39 and the gram-negative
Y. enterocolitica strain 8081 serotype O:8 were used;
bacterial infection models have been established in
these strains (Pramanik et al. 2007). A single dose of
1 mg/kg body weight of intraperitoneally injected
albomycin given 12 h post-infection cleared
S. pneumoniae administered into the peritoneum of
BALBc mice with a lethal dose of 400 colony
forming units (CFU). At 7 days post-infection, all
albomycin-treated mice had survived and contained
no detectable CFU in the blood, liver, and spleen. In
an experiment with 10 mg/kg body weight of albo-
mycin administered 8 and 14 h post-infection,
1,000 CFU/ml were found in the blood after 24 h;
untreated mice contained 3 9 10
10 CFU/ml. The values
obtained with albomycin were very similar to the values
obtained with amoxicillin.
Under laboratory conditions, spontaneous albomy-
cin-resistant bacteria occur at a frequency of 10
-4 to
10
-5. To examine whether the emergence of resistant
bacteria precludes the use of albomycin, growth of an
albomycin-resistant strain was compared with growth
of a sensitive strain. Mice were infected with a
mixture of wild-type (98.6%) and albomycin-resistant
(1.4%) S. pneumoniae cells. After 12, 20, 28, and 36 h
post-infection, blood was collected from the tail vein,
and the number of resistant and sensitive bacteria
were determined. At 20 h post-infection, the percent-
age of mutant cells in untreated mice decreased to
0–0.46%ofthetotalbacterialcells,whichindicatesthat
the mutant has a reduced ﬁtness in the mice. At 12 h
post-infection,themutantcellsamountedto0–2%ofthe
totalcellsinthealbomycin-treatedmice(5 mg/kgbody
weight). At 36 h post-infection, the percentage of
albomycin-resistant bacteria increased to 86–97%,
which indicates eradication of most of the sensitive
bacteria and selection for the resistant bacteria.
Mice are also cleared from Y. enterocolitica by
albomycin.Aninoculum of5 9 10
4 CFUperC57BL/
6 mouse yields a strong increase in the number of
bacteria in the spleen (Table 3). Administration of
albomycin 24 h post-infection strongly reduces the
CFU in the spleen. The number of albomycin-resistant
bacteria increases in mice treated with albomycin.
However, the CFU is nearly 3–4 orders of magnitude
lower than in untreated mice, which gives the immune
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Fig. 4 Competitiveness of the albomycin-resistant S. pneu-
moniae mutant D39T1 with the wild-type parent strain D39 in
mice. Mice (n = 12) were infected with a mixture of
1,000 CFU of strain D39 and 14 CFU of strain D39T1. After
12 h post-infection, six mice received placebo (PBS) and six
mice received albomycin (5 mg/kg body weight, thrice a day).
In 8 h intervals, blood samples were collected from the tail
vein of each mouse and the bacterial cells were counted. All
PBS-treated mice died within 26 h post-infection. Open
squares, CImutant from PBS-treated mice; ﬁlled triangles,
CImutant of albomycin-treated mice. CImutant = percentage of
mutant CFU in the total CFU/percentage of mutant CFU in the
inoculum CFU. A CImutant of 1 indicates that the mutant
proliferates as well as the wild-type, and a CFUmutant \1
indicates that the mutant multiplies less than the wild-type
Table 3 Development of
resistant Y. enterocolitica
8081 in mice
Albomycin was
administered 24 h post-
infection. CFU, colony
forming units
Total CFU/spleen Resistant CFU Percent resistant
Inoculum 5 9 10
4 5 0.01
30 h post-infection 3.9 9 10
6 00
48 h post-infection 4.8 9 10
7 290 0.0006
30 h post-infection with albomycin 7.8 9 10
3 10 0.13
48 h post-infection with albomycin 8 9 10
4 5 9 10
3 6.25
Biometals (2009) 22:3–13 11
123systemachancetocopewiththeinfection.Toexamine
proliferation of resistant bacteria, mice were inocu-
lated with a surplus ofsensitive over resistant bacteria.
Results obtained with S. pneumoniae are shown in
Fig. 4. In untreated mice, more wild-type than mutant
bacteria were found in the spleen. In the albomycin-
treated mice, the mutant bacteria overrode the wild-
type bacteria, which are killed by albomycin. In a
similar experiment done with Y. enterocolitica, wild-
type bacteria proliferate faster than albomycin-resis-
tant bacteria (Pramanik et al. 2007).
To examine the in vivo efﬁcacy of salmycin,
protection of mice by treatment with salmycin
against S. aureus infections (infection dosis: 10
8
bacterial cells) was tested. Salmycin A (10 mg/kg
body weight) administered 6 and 24 h post-infection
reduced the CFU of the S. aureus MRSA strain
COL in kidneys of CD1 mice 30-fold 48 h post-
infection and 80-fold 72 h post-infection (Fig. 5).
For comparison, in a control experiment with a
mixture of vancomycin and rifamycin (vancomycin
alone was ineffective), each at 10 lg/kg body
weight, the CFU was reduced 5 9 10
3- and
2 9 10
4-fold, respectively. Salmycin A is effective,
but should be administered at shorter intervals since
it rapidly loses activity. The optimal treatment was
not established.
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